Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any sex
• People who have been diagnosed with esophageal squamous cell carcinoma (a type of throat/food pipe cancer) confirmed by laboratory testing, where the cancer cannot be surgically removed and is either locally advanced, has returned, or has spread to other parts of the body
• People who have not previously received systemic (whole-body) anti-cancer treatment — though people who had chemotherapy as part of earlier treatment may still be considered if their cancer came back or got worse more than 6 months after their last chemotherapy dose
• People who have at least one measurable tumour that has not been treated with radiation (or, if it was, the tumour must be confirmed to have grown since then)
• People who are willing to provide a tissue sample (ideally a recent one, or stored tissue sections if a recent sample is not available) for laboratory testing
• People with a good general level of daily functioning, rated 0 or 1 on a standard medical activity scale (confirm with trial site)
• People who are able to swallow pills normally
• People whose life expectancy is at least 12 weeks
• People whose blood counts, liver function, kidney function, and other organ measurements meet the specific levels required by the trial (confirm with trial site)
• People who are willing and able to use medically approved contraception during treatment and for at least 2 months after the last dose of certain study drugs, and at least 6 months after the last dose of chemotherapy — this applies to people who could become pregnant and to men whose partners could become pregnant
• People who voluntarily agree to take part, sign a consent form, and are willing to attend follow-up appointments

Who may not be able to join:

• People with a body mass index (BMI) below 18.5, or who have lost 10% or more of their body weight in the 2 months before the screening assessment
• People who have coughed up blood in the 3 weeks before starting treatment, or who have had tumour-related bleeding in the 2 weeks before starting treatment
• People whose cancer is assessed by the trial doctor as having grown into nearby structures such as major blood vessels or the airway, creating a high risk of bleeding or a hole forming between organs
• People with a history of a hole or tear in the gastrointestinal tract (stomach or intestines), or who have had a bowel blockage within 3 months before joining, or who have current symptoms suggesting a bowel blockage
• People who have had an esophageal stent (a tube placed inside the food pipe) inserted, or who are expected to need one
• People who currently have significant fluid build-up around the lungs, heart, or abdomen that requires draining, or who had it drained for treatment within 1 month before joining
• People with high blood pressure that is not well controlled by medication (blood pressure 140/90 mmHg or higher)
• People who have a known allergy to any of the study drugs or their ingredients, including the immunotherapy drug (camrelizumab), apatinib mesylate, paclitaxel, albumin-bound paclitaxel, or cisplatin
• People who have taken another experimental drug within 4 weeks before starting the study
• People currently enrolled in another interventional clinical trial at the same time
• People who received anti-cancer treatment (including radiotherapy) within 4 weeks before starting the study
• People who needed regular high-dose steroid or immune-suppressing medication within 2 weeks before starting the study (some exceptions apply — confirm with trial site)
• People who received an anti-tumour vaccine or a live vaccine within 4 weeks before starting the study
• People who had major surgery or a serious injury within 4 weeks before starting the study
• People whose side effects from previous cancer treatment have not yet recovered to a mild or resolved level (with the exception of hair loss)
• People who have cancer that has spread to the brain or central nervous system
• People with a history of active autoimmune diseases (conditions where the immune system attacks the body), with some exceptions such as stable thyroid conditions managed with steady medication, type 1 diabetes on a steady insulin dose, or childhood asthma that has fully resolved (confirm with trial site)
• People with a history of immune deficiency conditions, HIV, organ transplant, or bone marrow transplant
• People with significant heart problems, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, or serious uncontrolled heart rhythm problems
• People who had a serious infection requiring hospitalisation within 4 weeks before starting the study, or who have signs of active lung inflammation or an active infection requiring antibiotic treatment at the time of starting
• People with a history of a scarring lung condition (interstitial lung disease) or non-infectious lung inflammation
• People with active tuberculosis (TB), or a history of TB within the past year, or a history of TB that was never properly treated
• People with active hepatitis B or hepatitis C infections at levels above specified thresholds (confirm with trial site)
• People who have had clinically significant bleeding — such as from the digestive tract or an ulcer — within 3 months before joining
• People who have had a blood clot or stroke event (including mini-strokes, brain bleeds, deep vein clots, or pulmonary embolism) within 6 months before joining
• People with a known inherited or acquired tendency to bleed or form clots (such as haemophilia or clotting disorders)
• People with active ulcers, wounds that have not healed, or bone fractures
• People with significant protein detected in the urine above a specified level (confirm with trial site)
• People currently taking certain medications known to strongly affect how the study drugs are processed by the body (specific drug types — confirm with trial site)
• People who have had another cancer diagnosed within the past 5 years, except for certain very low-risk skin cancers or treated cervical changes
• People who are pregnant or breastfeeding
• People who, in the trial doctor's judgement, have other serious medical, psychological, or social circumstances that could affect their safety or the reliability of the trial data

Important: Always verify eligibility with the trial site directly before applying.